Skip to content
Menu

KALA BIO, Inc. KALA

Full chart Compare
Set alert

Price alert · KALA

All alert types
3.04 USD +0.02 (+0.83%)

As ofNov 20, 2026, 11:31 AM EST

3.07 Day range 3.07
2.97 52-week range 2,865.00
YTD
-89.06%
1 year
-90.63%

5D -1.51 (-33.33%)

33.5044.50FriMonTueWed3.02
Market cap
1.98M
EPS (ttm)
-321.30
Shares out
4.61M
Forward P/E
-0.90
YTD return
-89.06%
1-year return
-90.63%
50-day average
6.42
200-day average
6.50
Volume
7.20K
Avg volume
52.28K
Open
3.07
Previous close
3.02
Day's range
3.07 – 3.07
52-week range
2.97 – 2,865.00
Beta
-2.14
Price target
15.00 (+393.4%)

Key statistics

Enterprise value
15.27M
Price / book
2.21
Free cash flow
-20.51M
Total cash
54.20M
Total debt
36.80M
Return on equity
-248.11%
Short % of float
0.85%

Fundamental scorecard

6 of 25 checks passed on KALA’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
KALA Revenue — quarterly 0
KALA Net income — quarterly -1.58M
KALA EPS — quarterly -640.00

Earnings

KALA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-2.43-1.93+0.50+20.58%
Aug 6, 2024Jun 1, 2024-4.41-3.16+1.25+28.34%
May 14, 2024Mar 1, 2024-2.89-4.20-1.31-45.33%
Mar 29, 2024Dec 1, 2023-3.62-3.18+0.44+12.15%
Nov 13, 2023Sep 1, 2023-2.15-3.41-1.26-58.60%
Aug 4, 2023Jun 1, 2023-3.19-4.36-1.17-36.68%

Upgrades / downgrades

KALA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 15, 2024HC Wainwright & Co.reitBuyBuy
Aug 19, 2024OppenheimerreitOutperformOutperform
May 17, 2024HC Wainwright & Co.mainBuyBuy
Apr 2, 2024HC Wainwright & Co.mainBuyBuy
Apr 1, 2024OppenheimerreitOutperformOutperform
Nov 17, 2023HC Wainwright & Co.mainBuyBuy

About KALA BIO, Inc.

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
kalarx.com

News

Your note

Sign in to keep a note on KALA — it syncs with the Stock Master app.

Insider holders

KALA insider holders
InsiderRelationLatest transactionDateShares held
BAZEMORE TODD MPresidentSaleJun 25, 202422,385
BLUMENKRANZ MARK SDirectorStock Award(Grant)Jun 10, 2024182,821
BRAZZELL ROMULUS KIMOfficerSaleJun 25, 202483,982
IWICKI MARK T.Chief Executive OfficerSaleJun 25, 2024263,755
KHARABI DARIUSOfficerSaleJun 25, 202459,728
KOVEN ANDREW IANDirectorStock Award(Grant)Jun 10, 202413,922

Institution ownership

KALA institution ownership
Holder% heldSharesValueReported
Baker Bros. Advisors, LP19.33%891,3355.35MSep 29, 2024
SR One Capital Management, LP9.62%443,6612.66MSep 29, 2024
Adar1 Capital Management, LLC 6.64%306,0671.84MSep 29, 2024
O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC)3.53%162,663975.98KSep 29, 2024
Millennium Management Llc3.05%140,731844.39KSep 29, 2024
Vanguard Group Inc1.16%53,570321.42KSep 29, 2024

Fund ownership

KALA fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund0.57%26,442158.65KSep 29, 2024
Vanguard Extended Market Index Fund0.57%26,296157.78KSep 29, 2024
Fidelity Extended Market Index Fund0.45%20,825124.95KOct 30, 2024
Fidelity Total Market Index Fund0.18%8,35150.11KOct 30, 2024
Fidelity Series Total Market Index Fund0.11%4,99729.98KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.03%1,4828.89KOct 30, 2024